Yiqiao Shenzhou (301047.SZ): 2023 equity distribution of 10 distributions of 20 yuan Equity Registration Day May 22

Gelonghui, May 16 | Yiqiao Shenzhou (301047.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 20.0000 (tax included) to all shareholders for every 10 shares based on the company's current total share capital excluding 127,760,391 shares after 1,439,609 shares already repurchased. The share registration date for this equity distribution is May 22, 2024, and the ex-dividend date is May 23, 2024.

Gelonghui FinanceMay 16 05:58 ET

Yiqiao Shenzhou (301047.SZ): Currently, pharmaceutical companies account for a relatively large share of direct sales revenue

Gelonghui May 10 丨 Yiqiao Shenzhou (301047.SZ) held a performance briefing on May 9, 2024 to discuss “What is the company's business share in scientific research institutions and pharmaceutical companies?” The company replied that the company's product line covers a wide range of products and can be used to support basic life science research by scientific research institutions and innovative research and development by pharmaceutical companies, and that there are different domestic and international competition situations in different fields of reagents and services. Currently, pharmaceutical companies account for a relatively large share of direct sales revenue.

Gelonghui FinanceMay 10 03:09 ET

Yiqiao Shenzhou (301047.SZ): The Bioengineering Center (C4B) in Houston, Texas has officially started operation

Gelonghui, May 10, 丨 Yiqiao Shenzhou (301047.SZ) held a performance briefing on May 9, 2024. Regarding “The company's annual report did not disclose the business development of US companies, how did the US business develop last year?” The company replied that the US subsidiary's business continued to develop steadily in 2023. The Bioengineering Center (C4B) in Houston, Texas has officially started operation to undertake customer service projects. In the future, it will take advantage of localization to better serve overseas research institutions and innovative pharmaceutical companies.

Gelonghui FinanceMay 10 03:08 ET

Sino BiologicalInc's (SZSE:301047) Earnings Quality Is Low

Sino Biological,Inc.'s (SZSE:301047) stock wasn't much affected by its recent lackluster earnings numbers. We did some analysis and found some concerning details beneath the statutory profit number.

Simply Wall StMay 5 20:38 ET

Following Recent Decline, Sino Biological,Inc.'s (SZSE:301047) Top Shareholder President Liangzhi Xie Sees Holdings Value Drop by 4.0%

Key Insights Sino BiologicalInc's significant insider ownership suggests inherent interests in company's expansion Liangzhi Xie owns 53% of the company Institutional ownership in Sino BiologicalI

Simply Wall StApr 8 18:21 ET

Yiqiao Shenzhou (301047.SZ): 1.11% of shares have been repurchased

Gelonghui, April 2, 丨 Yiqiao Shenzhou (301047.SZ) announced that as of March 31, 2024, the company used its own funds to carry out repurchases through centralized bidding transactions through a special stock repurchase account. The cumulative number of shares repurchased was 1,439,609 shares, accounting for 1.11% of the company's current total share capital. The maximum transaction price was RMB 74.67 yuan/share, and the minimum transaction price was RMB 69.86 per share, and the total transaction amount was RMB 10,37.45 million (excluding transaction fees).

Gelonghui FinanceApr 2 05:35 ET